IT'S HANBUL Posts Strong Q1 2026 Results with Revenue of 426.8B Won and Operating Profit of 68.3B Won

Consolidated Q1 2026 revenue: 426.8B KRW (+17.5% YoY), operating profit: 68.3B KRW (+22.4%), net profit attributable to parent: 94.1B KRW
Separate Q1 revenue: 7.1B KRW, operating loss of 1.5B KRW (swing to loss), but net profit of 9.2B KRW due to equity method gains (4.1B)
Dividend per share raised to 275 KRW (FY2025) from 250 KRW, total payout 4.8B KRW
Cash and cash equivalents: 49.9B KRW; net debt ratio negative; very solid financial position
Consolidated operating margin improved to 16.0% (from 15.4% YoY); new channels (online, H&B) account for 40.9% of revenue
Holds 4.31M treasury shares (19.67%); potential for additional shareholder returns
One pending lawsuit (1.4B KRW) but management expects no material impact
Subsidiary NeoPharm (41.11% stake) strong: revenue 36.2B KRW, net profit 8.6B KRW